U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Biliary Tract Carcinoma

MedGen UID:
1649667
•Concept ID:
C4745064
•
Neoplastic Process

Definition

The reemergence of a carcinoma arising from any part of the biliary tract after a period of remission. [from NCI]

Professional guidelines

PubMed

Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.
Chiorean EG, Chiaro MD, Tempero MA, Malafa MP, Benson AB, Cardin DB, Christensen JA, Chung V, Czito B, Dillhoff M, Donahue TR, Dotan E, Fountzilas C, Glazer ES, Hardacre J, Hawkins WG, Klute K, Ko AH, Kunstman JW, LoConte N, Lowy AM, Masood A, Moravek C, Nakakura EK, Narang AK, Nardo L, Obando J, Polanco PM, Reddy S, Reyngold M, Scaife C, Shen J, Truty MJ, Vollmer C, Wolff RA, Wolpin BM, Rn BM, Lubin S, Darlow SD
J Natl Compr Canc Netw 2023 Jul;21(7):753-782. doi: 10.6004/jnccn.2023.0034. PMID: 37433437
Surgical management of intrahepatic cholangiocarcinoma in the modern era: advances and challenges.
Konstantinidis IT, Arkadopoulos N, Ferrone CR
Chin Clin Oncol 2016 Feb;5(1):9. doi: 10.3978/j.issn.2304-3865.2016.02.06. PMID: 26932433
Liver transplantation for cholangiocarcinoma: current best practice.
DeOliveira ML
Curr Opin Organ Transplant 2014 Jun;19(3):245-52. doi: 10.1097/MOT.0000000000000087. PMID: 24811436

Recent clinical studies

Etiology

Survival Benefits of Surgical Resection in Patients with Recurrent Biliary Tract Carcinoma.
Motoyama H, Kobayashi A, Yokoyama T, Shimizu A, Kitagawa N, Notake T, Fukushima K, Masuo H, Yoshizawa T, Miyagawa SI
World J Surg 2017 Nov;41(11):2817-2829. doi: 10.1007/s00268-017-4107-3. PMID: 28717913

Diagnosis

Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma.
Ohtaka K, Kohya N, Sato K, Kitajima Y, Ide T, Mitsuno M, Miyazaki K
Oncol Rep 2008 Aug;20(2):279-86. PMID: 18636187
Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for recurrent/metastatic biliary tract carcinoma.
Lim JY, Jeung HC, Mun HS, Lee DK, Paik YH, Lee SJ, Yoon DS, Cho JY
Anticancer Drugs 2008 Jul;19(6):631-5. doi: 10.1097/CAD.0b013e3283017f94. PMID: 18525323

Therapy

Survival Benefits of Surgical Resection in Patients with Recurrent Biliary Tract Carcinoma.
Motoyama H, Kobayashi A, Yokoyama T, Shimizu A, Kitagawa N, Notake T, Fukushima K, Masuo H, Yoshizawa T, Miyagawa SI
World J Surg 2017 Nov;41(11):2817-2829. doi: 10.1007/s00268-017-4107-3. PMID: 28717913
Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma.
Ohtaka K, Kohya N, Sato K, Kitajima Y, Ide T, Mitsuno M, Miyazaki K
Oncol Rep 2008 Aug;20(2):279-86. PMID: 18636187
Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for recurrent/metastatic biliary tract carcinoma.
Lim JY, Jeung HC, Mun HS, Lee DK, Paik YH, Lee SJ, Yoon DS, Cho JY
Anticancer Drugs 2008 Jul;19(6):631-5. doi: 10.1097/CAD.0b013e3283017f94. PMID: 18525323
The efficacy of epirubicin, cisplatin, uracil/tegafur, and leucovorin in patients with advanced biliary tract carcinoma.
Park KH, Choi IK, Kim SJ, Oh SC, Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS
Cancer 2005 Jun 1;103(11):2338-43. doi: 10.1002/cncr.21041. PMID: 15825161

Prognosis

Survival Benefits of Surgical Resection in Patients with Recurrent Biliary Tract Carcinoma.
Motoyama H, Kobayashi A, Yokoyama T, Shimizu A, Kitagawa N, Notake T, Fukushima K, Masuo H, Yoshizawa T, Miyagawa SI
World J Surg 2017 Nov;41(11):2817-2829. doi: 10.1007/s00268-017-4107-3. PMID: 28717913
Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma.
Ohtaka K, Kohya N, Sato K, Kitajima Y, Ide T, Mitsuno M, Miyazaki K
Oncol Rep 2008 Aug;20(2):279-86. PMID: 18636187
The efficacy of epirubicin, cisplatin, uracil/tegafur, and leucovorin in patients with advanced biliary tract carcinoma.
Park KH, Choi IK, Kim SJ, Oh SC, Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS
Cancer 2005 Jun 1;103(11):2338-43. doi: 10.1002/cncr.21041. PMID: 15825161

Clinical prediction guides

Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for recurrent/metastatic biliary tract carcinoma.
Lim JY, Jeung HC, Mun HS, Lee DK, Paik YH, Lee SJ, Yoon DS, Cho JY
Anticancer Drugs 2008 Jul;19(6):631-5. doi: 10.1097/CAD.0b013e3283017f94. PMID: 18525323

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...